California is currently home to 5955 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Los Angeles, San Francisco, San Diego and Sacramento. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Narrative Medicine for Improving Well-Being in Patients With Gastrointestinal Cancers
Recruiting
This clinical trial assesses whether narrative medicine methods may improve the sense of well-being among gastrointestinal (GI) (digestive system) cancer patients. Narrative medicine is a clinical approach where providers can use a patient's own narrative (perspective) of their illness to promote healing and resilience. By applying narrative medicine's main tool, close reading, to clinical practice, clinicians learn to listen and attend to patients more deeply. This allows for freer communicatio... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
04/17/2024
Locations: USC / Norris Comprehensive Cancer Center, Los Angeles, California
Conditions: Malignant Digestive System Neoplasm
A Research Study Comparing How Well Different Doses of the Medicine NN0519-0130 Help People With Excess Body Weight Lose Weight
Recruiting
This study will look at how a new medicine called NNC0519-0130 helps people with excess body weight lose weight. The study will test up to 6 different doses of NNC0519-0130. Participants will take 1-2 injections once a week. The study medicine will be injected under skin with a thin needle in the stomach, thigh, or upper arm. The study will last for about 42 weeks.
Gender:
All
Ages:
Between 18 years and 75 years
Trial Updated:
04/17/2024
Locations: FDRC, Costa Mesa, California
Conditions: Obesity
A Research Study Comparing How Well Different Doses of the Medicine NN0519-0130 Lower Blood Sugar in People With Type 2 Diabetes
Recruiting
This study will look at how well a new medicine called NNC0519-0130 helps people with type 2 diabetes lower their blood sugar and body weight. The study will test up to 7 different doses of NNC0519-0130. Which treatment participant will get is decided by chance. Participants will take 1-3 injections once a week. The study medicine will be injected under skin with a thin needle in the stomach, thigh, or upper arm. The study will last for about 40 weeks.
Gender:
All
Ages:
Between 18 years and 75 years
Trial Updated:
04/17/2024
Locations: Velocity Clin Res-Chula Vista, Chula Vista, California
Conditions: Diabetes Mellitus, Type 2
Study of V117957 in Interstitial Cystitis/Bladder Pain Syndrome
Recruiting
The purpose of this study is to evaluate the safety, tolerability and efficacy of V117957 in subjects with interstitial cystitis/bladder pain syndrome, compared to placebo.
Gender:
Female
Ages:
18 years and above
Trial Updated:
04/17/2024
Locations: Investigational Site, Escondido, California
Conditions: Interstitial Cystitis/Bladder Pain Syndrome
A Research Study to See How Well New Weekly Medicine IcoSema, Which is a Combination of Insulin Icodec and Semaglutide, Controls Blood Sugar Levels in People With Type 2 Diabetes (T2D), Compared to Daily Insulin Glargine (COMBINE 4)
Recruiting
This study will compare the new medicine IcoSema, which is a combination of insulin icodec and semaglutide, taken once a week, to insulin glargine (mentioned as insulin glargine in this form) taken daily in people with type 2 diabetes. The study will look at how well IcoSema controls blood sugar levels as compared to insulin glargine in people with type 2 diabetes who do not have their blood sugar properly controlled with other oral diabetes medicines. Participant will either get IcoSema or insu... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
04/17/2024
Locations: Scripps Whittier Diabetes Inst, La Jolla, California
Conditions: Type 2 Diabetes
A Study to Assess Adverse Events and Change in Disease Activity From Intravenous (IV) and Subcutaneous (SC) Lutikizumab in Adult Participants With Active Ulcerative Colitis
Recruiting
Ulcerative colitis (UC) is a type of inflammatory bowel disease that causes inflammation and bleeding from the lining of the rectum and colon (large intestine). The purpose of this study is to assess how safe and effective lutikizumab is in adult subjects with UC and how lutikizumab compares to adalimumab in the treatment of UC. Adverse events and changes in disease activity will be assessed. Lutikizumab is an investigational product being developed for the treatment of UC. Participants are pla... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
04/17/2024
Locations: Gastro SB /ID# 258331, Chula Vista, California
Conditions: Ulcerative Colitis
A Study of LY3841136 Compared With Placebo in Adult Participants With Obesity or Overweight
Recruiting
The main purpose of this study, performed under the master protocol W8M-MC-CWMM (NCT06143956), is to investigate weight management efficacy and safety with LY3841136 compared with placebo in adult participants with obesity or overweight. The study will last about 64 weeks and may include up to 13 visits.
Gender:
All
Ages:
Between 18 years and 75 years
Trial Updated:
04/17/2024
Locations: NorCal Medical Research, Inc, Greenbrae, California
Conditions: Obesity, Overweight and Obesity
Study to Evaluate Safety and Immunogenicity of a Prime-Boost Regimen of rVSV-Nipah Virus Vaccine Candidate PHV02 in Healthy Adult Subjects
Recruiting
The goal of this clinical trial is to test the safety and immunogenicity of PHV02 live, attenuated recombinant vesicular stomatitis virus vaccine expressing the Nipah Virus glycoprotein in healthy adult subjects. The main questions it aims to answer are: which doses of PHV02 are safe to administer to and well-tolerated by healthy adult subjects as a 2 dose regimen given 1 month apart? what is the immunologic response (Nipah-specific IgG ELISA antibody and neutralizing antibodies) to each dose l... Read More
Gender:
All
Ages:
Between 18 years and 59 years
Trial Updated:
04/17/2024
Locations: Cenexel ACT (Anaheim Clinical Trials), Anaheim, California
Conditions: Nipah Virus Infection
Safety and Efficacy of GS-100 Gene Therapy in Patients With NGLY1 Deficiency
Recruiting
A non-randomized, open-label, dose escalation study of a single intracerebroventricular (ICV) administration of a gene replacement therapy in subjects who are 2 to 18 years old with NGLY1 Deficiency.
Gender:
All
Ages:
Between 2 years and 18 years
Trial Updated:
04/17/2024
Locations: Oakland Children's Hospital (UCSF Benioff), Oakland, California
Conditions: NGLY1 Deficiency
Study of AZD9829 in CD123+ Hematological Malignancies
Recruiting
This is a modular, multicentre, open-label, Phase I/II, dose-setting study. AZD9829 will be administered intravenously as monotherapy or in combination in participants with CD123 positive hematological malignancies.
Gender:
All
Ages:
18 years and above
Trial Updated:
04/17/2024
Locations: Research Site, Duarte, California
Conditions: Hematological Malignancies
Study to Test the Drug Darolutamide Along With the Drugs Leuprolide Acetate and Exemestane in Patients With Recurrent Ovarian Granulosa Cell Tumors
Recruiting
This phase II trial tests how well darolutamide in combination with leuprolide acetate and exemestane works in treating patients with ovarian granulosa cell tumors that have come back after a period of improvement (recurrent). Darolutamide is in a class of medications called androgen receptor inhibitors. It works by blocking the effects of androgen (a male reproductive hormone) to stop the growth and spread of tumor cells. Leuprolide acetate is in a class of medications called gonadotropin-relea... Read More
Gender:
Female
Ages:
18 years and above
Trial Updated:
04/17/2024
Locations: Cedars Sinai Medical Center, Los Angeles, California
Conditions: Adult Ovarian Granulosa Cell Tumor
A Study to Describe the Characteristics, Health Care Interventions and Outcomes of Patients With Major Bleedings in the Presence of Factor Xa Inhibitor Treatment
Recruiting
REVERXaL study aims to increase the understanding of the patient characteristics, bleeding presentation, health care interventions provided, and the clinical as well as self-reported health outcomes of patients with major bleeding in the presence of Factor Xa inhibitor treatment. The generation of insight on treatment approaches and associated outcomes in hospitalized patients with Factor Xa inhibitor-related major bleeds may inform clinical guidelines, health system decision making and streamli... Read More
Gender:
All
Ages:
Between 18 years and 130 years
Trial Updated:
04/17/2024
Locations: Research Site, Orange, California
Conditions: Major Bleeding